Enhancing ADC Development with Anti-MMAE Antibodies

Monomethyl auristatin E (MMAE), a potent mitotic inhibitor derived from dolastatin 10, plays a pivotal role in antibody-drug conjugates (ADCs) for cancer therapy. By precisely targeting cancer cells, ADCs minimize collateral damage to healthy tissues. However, the development of ADCs requires extensive pharmacokinetic (PK) and safety evaluations.

Our specialized anti-MMAE antibodies streamline these processes, enabling more efficient PK analysis and safety assessments. These antibodies are essential tools in optimizing ADCs, ensuring their effectiveness and safety as they continue to transform cancer treatment.

View All Anti-MMAE Antibodies